Travere Therapeutics
TVTX
178 hedge funds and large institutions have $1.16B invested in Travere Therapeutics in 2024 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 62 increasing their positions, 58 reducing their positions, and 23 closing their positions.
57% more capital invested
Capital invested by funds: $736M → $1.16B (+$422M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
22% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 23
3% more funds holding
Funds holding: 173 → 178 (+5)
7% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 58
7.45% less ownership
Funds ownership: 115.66% → 108.2% (-7.5%)
17% less call options, than puts
Call options by funds: $12.4M | Put options by funds: $14.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$31.9M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$13.4M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$11.5M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$11.4M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$7.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$71.2M |
| 2 |
Millennium Management
New York
|
-$29.5M |
| 3 |
Morgan Stanley
New York
|
-$22.3M |
| 4 |
TF
Talbot Financial
Bellevue,
Washington
|
-$12.9M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$8.75M |
TVTX Hedge Fund Activity: Q3 2024 in Review
178 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q3 2024, worth a combined $1.16B — up 57% from $736M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new TVTX positions and 23 closed out — a net gain of 5 holders — while 62 added to existing stakes and 58 trimmed.
The largest buyer was Woodline Partners, adding an estimated $31.9M. The largest seller was Deep Track Capital, cutting an estimated $71.2M.
- 178 institutional investors held Travere Therapeutics (TVTX) as of Q3 2024, up from 173 in Q2 2024.
- Funds reported $1.16B of Travere Therapeutics stock for Q3 2024, up 57% quarter-over-quarter.
- 28 funds opened new Travere Therapeutics positions in Q3 2024 and 23 closed out, a net change of +5 holders.
- The largest Travere Therapeutics buyer in Q3 2024 was Woodline Partners, an estimated $31.9M added.
- The largest Travere Therapeutics seller in Q3 2024 was Deep Track Capital, an estimated $71.2M sold.
Based on aggregated 13F filings for Q3 2024.